Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC cut its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 31.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 281,863 shares of the company's stock after selling 131,774 shares during the period. TimesSquare Capital Management LLC owned approximately 0.22% of Vaxcyte worth $10,643,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. National Bank of Canada FI acquired a new position in shares of Vaxcyte in the fourth quarter valued at about $41,000. Parallel Advisors LLC boosted its stake in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after buying an additional 1,071 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Vaxcyte in the fourth quarter worth about $214,000. Nisa Investment Advisors LLC boosted its stake in shares of Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after buying an additional 293 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Vaxcyte in the fourth quarter worth about $248,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PCVX. Cantor Fitzgerald began coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Bank of America lowered their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Trading Up 1.3%

Shares of PCVX stock opened at $36.38 on Tuesday. The company has a market capitalization of $4.69 billion, a P/E ratio of -9.12 and a beta of 1.19. The business's 50 day moving average is $33.35 and its two-hundred day moving average is $54.73. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the prior year, the firm posted ($0.85) earnings per share. On average, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.